Instructions for Credit - There is no fee for this activity. To receive credit for this CE activity, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for 1.0 continuing education credit. Please retain a copy of the certificate for your records.

Target Audience:
Nurses, social workers and other healthcare professionals involved in the care of patients with hematologic malignancies. Course content level for social workers: intermediate and advanced

This webinar will provide a more in-depth overview of blood cancers. Pertinent information to be discussed will include the role of genomics and molecular profiling in the diagnosis, prognostication, treatment, and monitoring of patients with hematologic malignancies. The program will also explore the various treatment modalities available for blood cancer patients including clinical trials. Discussion of the psychosocial impact of the disease with the inclusion of resources for patient and caregiver education and support will be provided to aid the multidisciplinary healthcare team in providing relevant, scientific, and holistic care.

Learning Objectives:
At the conclusion of this program, participants will be able to:

  • Explain the role of genomics and molecular profiling in the diagnosis, prognostication, treatment, and monitoring of blood cancer.
  • Describe the psychosocial impact of different blood cancer diagnoses.
  • Explore treatment options for blood cancer patients including precision medicine, cellular therapy, and clinical trials.
  • List resources for patients with blood cancers and how to access them.

Laura Romundstad, CRNP, MSN, RN
Clinical Trial Nurse Navigator
Clinical Trial Support Center
The Leukemia & Lymphoma Society
Rye Brook, NY

Lynn Steele, LSW, OSW-C
Information Specialist
Information Resource Center
The Leukemia & Lymphoma Society
Rye Brook, NY

Continuing Education Information:
Registered Nursing Credit Designation
Approval for nurses has been obtained by the The Leukemia & Lymphoma Society National Office under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Social Work Credit Designation
The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations not individual courses are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2023 to 12/10/2026. Social workers completing this course receive 1.0 continuing education credit.

LLS is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.

All continuing education credits are provided free of charge.

Participants must attend the webinar in its entirety and submit the online evaluation form to earn credit. Once submitted, the certificate will be generated as a PDF online.

There are no system requirements other than an internet connection.

Disclosure of Conflicts of Interest:
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by The Leukemia & Lymphoma Society for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity during the past 12 months.

Faculty Disclosures:
Laura Romundstad, CRNP, MSN, RN has no affiliations to disclose.
Lynn Steele, LSW, OSW-C has no affiliations to disclose.

Disclaimer: The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

At the time of this presentation, there were treatments noted to be in trials and pending FDA approval that may have since been FDA approved. A list of FDA approved treatments to treat blood cancers can be accessed at:

Provider: The Leukemia & Lymphoma Society
Estimated time to complete activity: 1.0 hour
Date of initial release: December 8, 2021
Valid for CE credit through: December 8, 2024

For questions, concerns, or for assistance for people with disabilities or grievances, please contact